• Investors may be considering whether Masimo, at around US$178 per share, still offers value or if much of the opportunity is already reflected in the price.
• The stock has posted a 40.1% return year to date and a 6.5% return over the last 12 months, with shorter term moves of 1.7% over 7 days and 1.9% over 30 days.
• These returns have come alongside ongoing attention on Masimo's role in medical technology and its position in the broader healthcare sector. Recent headlines have continued to focus on how the company is positioning its products and technology, which helps frame how investors think about both risk and potential.
• Even with this backdrop, Masimo currently has a value score of 1 out of 6. The next sections will walk through how different valuation methods assess the stock and will conclude with a way to tie those methods together into a more complete view of value.

Masimo scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Masimo Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting future cash flows and discounting them back to today using a required rate of return. It is essentially asking what those future dollars are worth in current terms.

For Masimo, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $172.7 million. Based on analyst input for 2026 and further projections by Simply Wall St, free cash flow is expected to reach about $412.4 million in 2035, with annual figures along the way discounted back to today.

Adding these discounted cash flows together leads to an estimated intrinsic value of about $127.55 per share. Compared with the recent share price of around $178, the DCF output indicates that Masimo is about 39.9% overvalued according to this model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Masimo may be overvalued by 39.9%. Discover 55 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Masimo Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much investors are paying for each dollar of earnings. It ties the share price directly to the bottom line, which is what ultimately supports long term valuations.

What counts as a “normal” P/E depends on how the market views growth potential and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually points to a lower one.

Masimo currently trades on a P/E of 44.9x. This is below the peer average of 52.4x but above the Medical Equipment industry average of 27.4x. Simply Wall St’s Fair Ratio for Masimo is 24.7x, which is its proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margin, market cap and risks.

The Fair Ratio can be more informative than a simple comparison with peers or the broad industry because it adjusts for Masimo’s own characteristics rather than assuming all companies deserve similar multiples. With the current P/E of 44.9x above the Fair Ratio of 24.7x, this approach points to the shares looking overvalued on an earnings basis.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Masimo Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you create about Masimo that link your view of its products, risks and opportunities to a set of numbers like future revenue, earnings, margins and a fair value. You can then compare that fair value with the current price to decide whether the stock looks attractive or not, all within an easy tool on Simply Wall St's Community page that updates automatically when fresh news or earnings arrive. For example, one Masimo Narrative might lean closer to the higher US$210 analyst price target by assuming stronger earnings and a higher future P/E, while another might sit nearer the US$170 target by using more cautious revenue and margin assumptions. This shows how different but clearly defined stories can live side by side and be tracked over time.

Do you think there's more to the story for Masimo? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.